Nav: Home

Surprising culprit in nerve cell damage identified

March 23, 2017

In many neurodegenerative conditions -- Parkinson's disease, amyotrophic lateral sclerosis (ALS) and peripheral neuropathy among them -- an early defect is the loss of axons, the wiring of the nervous system. When axons are lost, nerve cells can't communicate as they should, and nervous system function is impaired. In peripheral neuropathy in particular, and perhaps other diseases, sick axons trigger a self-destruct program.

In new research, scientists at Washington University School of Medicine in St. Louis have implicated a specific molecule in the self-destruction of axons. Understanding just how that damage occurs may help researchers find a way to halt it.

The study is published March 22 in the journal Neuron.

"Axons break down in a lot of neurodegenerative diseases," said senior author Jeffrey D. Milbrandt, MD, PhD, the James S. McDonnell Professor and head of the Department of Genetics. "Despite the fact these diseases have different causes, they are all likely rooted in the same pathway that triggers axon degeneration. If we could find a way to block the pathway, it could be beneficial for many different kinds of patients."

Since the molecular pathway that leads to loss of axons appears to do more harm than good, it's not clear what role this self-destruct mechanism plays in normal life. But scientists suspect that if the pathway that destroys axons could be paused or halted, it would slow or prevent the gradual loss of nervous system function and the debilitating symptoms that result. One such condition, peripheral neuropathy, affects about 20 million people in the United States. It often develops following chemotherapy or from nerve damage associated with diabetes, and can cause persistent pain, burning, stinging, itching, numbness and muscle weakness.

"Peripheral neuropathy is by far the most common neurodegenerative disease," said co-author Aaron DiAntonio, MD, PhD, the Alan A. and Edith L. Wolff Professor of Developmental Biology. "Patients don't die from it, but it has a huge impact on quality of life."

In previous studies, Stefanie Geisler, MD, an assistant professor of neurology, working with DiAntonio and Milbrandt, showed that blocking this axon self-destruction pathway prevented the development of peripheral neuropathy in mice treated with the chemotherapy agent vincristine. The hope is that if methods are developed to block this pathway in people, then it might be possible to slow or prevent the development of neuropathy in patients.

Toward that end, the Milbrandt and DiAntonio labs showed that a molecule called SARM1 is a central player in the self-destruct pathway of axons. In healthy neurons, SARM1 is present but inactive. For reasons that are unclear, injury or disease activate SARM1, which sets off a series of events that drains a key cellular fuel -- called nicotinamide adenine dinucleotide (NAD) -- and leads to destruction of the axon. Though the researchers previously had shown SARM1 was required for this chain of events to play out, the details of the process were unknown.

SARM1 and similar molecules -- those containing what are called TIR domains -- most often are studied in the context of immunity, where these domains serve as scaffolds. Essentially, TIR domains provide a haven for the assembly of molecules or proteins to perform their work.

The researchers had assumed that SARM1 acted as a scaffold to provide support for the work of destroying axons, beginning with the rapid loss of cellular fuel that occurs minutes after SARM1 becomes active. The scientists set about searching for the demolition crew -- the active molecule or molecules that use the SARM1 scaffold to carry out the demolition. The study's first author, Kow A. Essuman, a Howard Hughes Medical Institute Medical Research Fellow and an MD/PhD student in Milbrandt's lab, performed a litany of cellular and biochemical experiments searching for the demolition crew and came up empty.

"We performed multiple experiments but could not identify molecules that are traditionally known to consume NAD," Essuman said.

But as a last resort, the investigators tested SARM1 itself. To their great surprise, they found it was doing more than simply providing a passive platform. Specifically, the researchers showed SARM1's TIR domain acts as an enzyme, a molecule that carries out biochemical reactions, in this case destroying axons by first burning all their NAD cellular fuel.

"There are more than 1,000 papers describing the function of proteins containing TIR domains," DiAntonio said. "No one had ever shown that this type of molecule could be an enzyme. So we went into our experiments assuming SARM1 was only a scaffold and that there must be some other enzyme responsible for demolition of the axon. We essentially searched for a demolition crew, only to discover that the scaffold itself is destroying the structure. It's the last thing you would expect."

The findings suggest molecules similar to SARM1 -- those with TIR domains and known to serve as scaffolds in the immune system -- may prove to have additional functions that go beyond their structural roles. The research also invites a search for drugs that block the SARM1 enzyme from triggering axonal destruction.
-end-
This work was supported by the National Institutes of Health (NIH), grant numbers RO1NS065053, RO1AG013730, RO1NS087632, NCATS UL1 TR000448, NIGMS P41 GM103422 and NCI P30 CA091842; a Howard Hughes Medical Institute Medical Research Fellowship; and the Muscular Dystrophy Association, grant numbers MDA349925 and MDA344513. Washington University, Milbrandt and co-author Yo Sasaki may derive income from licensing of technology to ChromaDex.

Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J. The SARM1 Toll/Interleukin-1 Receptor (TIR) Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. Neuron. March 22, 2017.

Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked seventh in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Washington University School of Medicine

Related Neurodegenerative Diseases Articles:

Researchers identify link between birth defect and neurodegenerative diseases
A new study has found a link between neurological birth defects in infants commonly found in pregnant women with diabetes and several neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases.
High school football players, 1956-1970, did not have increase of neurodegenerative diseases
A Mayo Clinic study published online today in Mayo Clinic Proceedings found that varsity football players from 1956 to 1970 did not have an increased risk of degenerative brain diseases compared with athletes in other varsity sports.
Researchers reveal how neurodegenerative diseases spread through the brain
Synapses, the place where brain cells contact one another, play a pivotal role in the transmission of toxic proteins.
Untangling a cause of memory loss in neurodegenerative diseases
In mice genetically engineered to mimic aspects of human tauopathy disorders, the researchers restored some of the learning and memory deficits by blocking caspase-2 activity, which suggests that some of the cognitive loss seen in tauopathies might be reversible.
New impetus for treatment neurodegenerative diseases
Twenty years ago, tumor necrosis factor (TNF) seemed a promising target in the treatment of brain diseases like multiple sclerosis or Alzheimer's Disease.
Study demonstrates role of gut bacteria in neurodegenerative diseases
Research has revealed that exposure to bacterial proteins called amyloid that have structural similarity to brain proteins may lead to an increase in clumping of proteins in the brain.
How do the bugs in your gut affect neurodegenerative and psychiatric diseases?
A growing body of scientific and medical evidence continues to shed light on the complex interaction between metabolic pathways affected by microrganisms living in the human gut and gene expression, immune function, and inflammation that can contribute to a range of cognitive, psychiatric, and neurodegenerative disorders.
Antioxidant therapies may help in the fight against neurodegenerative diseases
A new review examines the potential of antioxidant approaches for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis.
Promising results with new gene therapy approach for treating inherited neurodegenerative diseases
A new gene therapy approach designed to replace the enzyme that is deficient in patients with the inherited neurodegenerative disorders Tay-Sachs and Sandhoff diseases successfully delivered the therapeutic gene to the brains of treated mice, restored enzyme function, and extended survival by about 2.5-fold.
Could a new class of fungicides play a role in autism, neurodegenerative diseases?
Scientists at the UNC School of Medicine have found a class of commonly used fungicides that produce gene expression changes similar to those in people with autism and neurodegenerative conditions, including Alzheimer's disease and Huntington's disease.

Related Neurodegenerative Diseases Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...